+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncternal Therapeutics (ONCT) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 50 Pages
  • June 2023
  • GlobalData
  • ID: 1291960
Oncternal Therapeutics (ONCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oncternal Therapeutics (Oncternal), formerly GTx Inc, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company's has pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid lukemia and a ROR1-targeted CAR-T therapy candidate for treatment hematologic and solid tumors. It conducts preclinical development activities in the US and Europe. Oncternal is headquartered in San Diego, California, the US.

Oncternal Therapeutics Key Recent Developments

  • May 04, 2023: Oncternal Therapeutics provides business update and announces first quarter 2023 financial results
  • Apr 27, 2023: Oncternal Therapeutics to provide business update and report first quarter 2023 financial results
  • Mar 09, 2023: Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
  • Mar 02, 2023: Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Oncternal Therapeutics - Key Facts
  • Oncternal Therapeutics - Key Employees
  • Oncternal Therapeutics - Key Employee Biographies
  • Oncternal Therapeutics - Major Products and Services
  • Oncternal Therapeutics - History
  • Oncternal Therapeutics - Company Statement
  • Oncternal Therapeutics - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Oncternal Therapeutics - Business Description
  • R&D Overview
  • Oncternal Therapeutics - Corporate Strategy
  • Oncternal Therapeutics - SWOT Analysis
  • SWOT Analysis - Overview
  • Oncternal Therapeutics - Strengths
  • Oncternal Therapeutics - Weaknesses
  • Oncternal Therapeutics - Opportunities
  • Oncternal Therapeutics - Threats
  • Oncternal Therapeutics - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Oncternal Therapeutics, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 04, 2023: Oncternal Therapeutics provides business update and announces first quarter 2023 financial results
  • Apr 27, 2023: Oncternal Therapeutics to provide business update and report first quarter 2023 financial results
  • Mar 09, 2023: Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
  • Mar 02, 2023: Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results
  • Jan 04, 2023: Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors
  • Oct 27, 2022: Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results
  • Aug 09, 2022: Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
  • Aug 02, 2022: Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results
  • May 05, 2022: Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
  • Apr 28, 2022: Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Oncternal Therapeutics, Key Facts
  • Oncternal Therapeutics, Key Employees
  • Oncternal Therapeutics, Key Employee Biographies
  • Oncternal Therapeutics, Major Products and Services
  • Oncternal Therapeutics, History
  • Oncternal Therapeutics, Subsidiaries
  • Oncternal Therapeutics, Key Competitors
  • Oncternal Therapeutics, Ratios based on current share price
  • Oncternal Therapeutics, Annual Ratios
  • Oncternal Therapeutics, Interim Ratios
  • Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Oncternal Therapeutics, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Oncternal Therapeutics, Performance Chart (2018 - 2022)
  • Oncternal Therapeutics, Ratio Charts
  • Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oncternal Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Epizyme Inc
  • Juno Therapeutics Inc
  • Juno Therapeutics Inc
  • Epizyme Inc
  • Gilead Sciences Inc
  • ArQule Inc
  • Johnson & Johnson
  • Pfizer Inc
  • Novartis Pharmaceuticals Corp
  • TG Therapeutics Inc
  • NanoValent Pharmaceuticals Inc
  • Novartis Pharmaceuticals Corp
  • Pfizer Inc
  • Johnson & Johnson
  • ArQule Inc
  • TG Therapeutics Inc
  • NanoValent Pharmaceuticals Inc
  • Gilead Sciences Inc